Additionally, NCT04652440, a phase II, single-arm, single-center study, is assessing the safety and tolerability of combining radiofrequency or microwave ablation with a PD-1 monoclonal antibody in HCC patients [125]. Here, PDCD1 is linked to hepatocellular carcinoma.